SPP1 (Secreted Phosphoprotein 1, also known as Osteopontin) encodes a secreted matricellular glycoprotein that functions as a cytokine, chemokine, and extracellular matrix protein. Osteopontin is expressed throughout the central nervous system by [neurons](/cell-types/neurons), [astrocytes](/cell-types/astrocytes), [microglia](/cell-types/microglia-neuroinflammation), and [oligodendrocytes](/cell-types/oligodendrocytes). It plays critical roles in neuroinflammation, cell survival, synaptic plasticity, myelination, and blood-brain barrier (BBB) regulation. Elevated SPP1 expression is observed in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and other neurodegenerative conditions, positioning osteopontin as both a potential biomarker and therapeutic target. [@ramesh2019]
The SPP1 protein is a member of the small integrin-binding ligand N-linked glycoprotein (SIBLING) family. It contains an arginine-glycine-aspartic acid (RGD) sequence that mediates integrin binding, as well as multiple cleavage sites for proteases including thrombin and matrix metalloproteinases (MMPs). These structural features enable osteopontin to interact with multiple receptors including integrins (αvβ3, α4β1, α5β1) and CD44, triggering diverse downstream signaling pathways. [@chio2020]
SPP1 (Secreted Phosphoprotein 1, also known as Osteopontin) encodes a secreted matricellular glycoprotein that functions as a cytokine, chemokine, and extracellular matrix protein. Osteopontin is expressed throughout the central nervous system by [neurons](/cell-types/neurons), [astrocytes](/cell-types/astrocytes), [microglia](/cell-types/microglia-neuroinflammation), and [oligodendrocytes](/cell-types/oligodendrocytes). It plays critical roles in neuroinflammation, cell survival, synaptic plasticity, myelination, and blood-brain barrier (BBB) regulation. Elevated SPP1 expression is observed in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and other neurodegenerative conditions, positioning osteopontin as both a potential biomarker and therapeutic target. [@ramesh2019]
The SPP1 protein is a member of the small integrin-binding ligand N-linked glycoprotein (SIBLING) family. It contains an arginine-glycine-aspartic acid (RGD) sequence that mediates integrin binding, as well as multiple cleavage sites for proteases including thrombin and matrix metalloproteinases (MMPs). These structural features enable osteopontin to interact with multiple receptors including integrins (αvβ3, α4β1, α5β1) and CD44, triggering diverse downstream signaling pathways. [@chio2020]
<div class="infobox infobox-gene">
| Property | Value |
|----------|-------|
| Gene Symbol | SPP1 |
| Gene Name | Secreted Phosphoprotein 1 (Osteopontin) |
| Chromosomal Location | 4q21.1 |
| NCBI Gene ID | [6696](https://www.ncbi.nlm.nih.gov/gene/6696) |
| OMIM | [166490](https://www.omim.org/entry/166490) |
| UniProt | [P08421](https://www.uniprot.org/uniprot/P08421) |
| Ensembl | [ENSG00000118733](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000118733) |
| RefSeq mRNA | NM_001040084 |
| Protein Length | 314 amino acids |
</div>
Osteopontin possesses several structural features that mediate its functions:
Cytokine and Chemokine Activity: Osteopontin functions as a pro-inflammatory cytokine, recruiting immune cells to sites of injury and activating microglia and macrophages. It signals through both integrin-dependent and CD44-mediated pathways. [@ramesh2019]
Cell Survival and Adhesion: Through integrin signaling, osteopontin promotes neuronal survival via the PI3K/Akt and MAPK pathways. It also mediates cell-matrix adhesion and migration.
Extracellular Matrix Remodeling: Osteopontin interacts with collagen and fibronectin, contributing to extracellular matrix organization and repair.
Immunomodulation: Osteopontin influences T-cell differentiation, macrophage polarization, and cytokine production, modulating both innate and adaptive immune responses.
Within the central nervous system, SPP1 is expressed in multiple cell types:
Neurons: Basal expression is moderate, with upregulation in response to excitotoxic injury and neurodegeneration.
Astrocytes: Reactive astrocytes show increased osteopontin expression, particularly in proximity to amyloid plaques and neurofibrillary tangles.
Microglia: Both resting and activated microglia express osteopontin. The protein is upregulated in response to inflammatory stimuli and co-localizes with microglial markers in diseased brain.
Oligodendrocytes: Osteopontin is expressed in oligodendrocyte precursor cells and mature oligodendrocytes, where it regulates differentiation and myelination.
Endothelial Cells: Cerebral endothelial cells express osteopontin, where it participates in BBB regulation and vascular remodeling.
Cerebrospinal fluid (CSF) osteopontin levels are elevated in multiple neurodegenerative diseases, making it a candidate biomarker. Serum levels also show disease-associated changes, though with less CNS specificity.
Osteopontin demonstrates multiple associations with AD pathogenesis:
Amyloid Pathology: SPP1 expression is elevated in AD brain tissue and co-localizes with amyloid plaques. Osteopontin may influence amyloid-beta (Aβ) aggregation and clearance through effects on microglial phagocytosis. [@brown2021]
Tau Pathology: Osteopontin interacts with hyperphosphorylated tau and is found in neurofibrillary tangles. The protein may promote tau aggregation and propagation. [@iyer2020]
Neuroinflammation: As a pro-inflammatory cytokine, osteopontin promotes microglial activation and cytokine release (IL-1β, TNF-α, IL-6), creating a feed-forward loop of neuroinflammation. [@careccia2019]
Synaptic Dysfunction: Osteopontin modulates synaptic plasticity and is implicated in synaptic loss in AD.
Genetic Associations: SPP1 polymorphisms influence AD risk and age of onset in some populations. The rs1126772 variant has been associated with increased AD risk. [@stern2020]
Biomarker Potential: CSF osteopontin levels are elevated in AD and correlate with disease severity and progression.
In PD, osteopontin exhibits complex relationships with alpha-synuclein pathology:
Alpha-Synuclein Interaction: Osteopontin may influence alpha-synuclein aggregation and clearance. Studies show altered expression in PD brains. [@kim2021]
Dopaminergic Neuron Vulnerability: SPP1 is upregulated in the substantia nigra of PD patients, where it may contribute to dopaminergic neuron death through effects on neuroinflammation and glial activation. [@maetzler2018]
Neuroinflammation: As in AD, osteopontin promotes microglial activation and neuroinflammation in PD.
Clinical Correlations: CSF osteopontin levels correlate with disease severity and motor symptom progression.
SERPINE1 plays significant roles in ALS pathophysiology:
Motor Neuron Vulnerability: Elevated osteopontin in ALS spinal cord and CSF, correlating with disease progression. The protein promotes neuroinflammation and microglial activation. [@comi2019]
Immune Dysregulation: Osteopontin levels correlate with disease severity and may serve as a biomarker.
Extracellular Matrix: ALS involves significant extracellular matrix remodeling, in which osteopontin plays a key role.
Osteopontin is particularly relevant to MS pathogenesis:
Demyelination and Remyelination: Osteopontin regulates oligodendrocyte precursor cell differentiation and myelination. It is elevated in demyelinating lesions and influences remyelination efficiency. [@hu2019]
Genetic Associations: SPP1 polymorphisms are linked to MS susceptibility in GWAS studies.
Immune Modulation: Osteopontin affects T-cell migration and cytokine production in autoimmune demyelination.
Osteopontin contributes to vascular contributions to cognitive decline:
Small Vessel Disease: Osteopontin promotes vascular inflammation and endothelial dysfunction in cerebral small vessels. [@zhang2022]
Blood-Brain Barrier: The protein affects BBB integrity and pericyte function in vascular cognitive impairment.
White Matter Damage: Osteopontin influences white matter integrity through effects on perfusion and inflammation.
FTD shows osteopontin elevations:
Osteopontin promotes neuroinflammation through multiple mechanisms:
Osteopontin contributes to BBB breakdown: [@wang2021]
Osteopontin affects synaptic plasticity:
Osteopontin interacts with aggregation-prone proteins:
The osteopontin pathway represents a therapeutic target:
Neutralizing Antibodies: Anti-osteopontin antibodies could reduce neuroinflammation. However, systemic effects may limit utility.
Small Molecule Inhibitors: Integrin receptor antagonists might block osteopontin signaling without affecting expression directly.
RNA-Based Approaches: Antisense oligonucleotides or siRNA could reduce SPP1 expression in the CNS.
Receptor Modulation: CD44 or integrin antagonists may provide benefit.
BBB Penetration: CNS-targeted delivery is essential for neurological applications.
Dual Roles: Osteopontin has both protective and pathogenic roles, complicating therapeutic targeting.
Biomarker Potential: Osteopontin may serve as both a diagnostic and prognostic biomarker in neurodegeneration.
Several rodent models inform SPP1 function:
Key areas for future investigation:
The following diagram shows the key molecular relationships involving SPP1 Gene discovered through SciDEX knowledge graph analysis: